Literature DB >> 12325083

An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype.

Parvoneh Poorkaj1, Nancy A Muma, Victoria Zhukareva, Elizabeth J Cochran, Kathleen M Shannon, Howard Hurtig, William C Koller, Thomas D Bird, John Q Trojanowski, Virginia M-Y Lee, Gerard D Schellenberg.   

Abstract

MAPT, the gene encoding tau, was screened for mutations in 96 progressive supranuclear palsy subjects. A point mutation (R5L) was identified in a single progressive supranuclear palsy subject that was not in the other progressive supranuclear palsy subjects or in 96 controls. Functionally, this mutation alters the ability of tau to promote microtubule assembly. Analysis of soluble tau from different brain regions indicates that the mutation does not affect the ratio of tau isoforms synthesized. Aggregated insoluble tau from subcortical regions was predominantly four-repeat tau with no or one amino terminal insert (0N4R and 1N4R). Insoluble tau from cortical regions also contained 1N3R tau. Thus, the R5L mutation causes a progressive supranuclear palsy phenotype, presumably by a gain-of-function mechanism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12325083     DOI: 10.1002/ana.10340

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  62 in total

1.  Transcriptome analysis of a tau overexpression model in rats implicates an early pro-inflammatory response.

Authors:  David B Wang; Robert D Dayton; Richard M Zweig; Ronald L Klein
Journal:  Exp Neurol       Date:  2010-03-24       Impact factor: 5.330

2.  LRP10 variants in progressive supranuclear palsy.

Authors:  Leonie J M Vergouw; Shamiram Melhem; Laura Donker Kaat; Wang Z Chiu; Demy J S Kuipers; Guido Breedveld; Agnita J W Boon; Li-San Wang; Adam C Naj; Elizabeth Mlynarksi; Laura Cantwell; Marialuisa Quadri; Owen A Ross; Dennis W Dickson; Gerard D Schellenberg; John C van Swieten; Vincenzo Bonifati; Frank Jan de Jong
Journal:  Neurobiol Aging       Date:  2020-04-30       Impact factor: 4.673

Review 3.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

4.  Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins.

Authors:  Ronald L Klein; Robert D Dayton; Nancy J Leidenheimer; Karen Jansen; Todd E Golde; Richard M Zweig
Journal:  Mol Ther       Date:  2005-12-01       Impact factor: 11.454

5.  Pathogenic missense MAPT mutations differentially modulate tau aggregation propensity at nucleation and extension steps.

Authors:  Edward Chang; Sohee Kim; Haishan Yin; Haikady N Nagaraja; Jeff Kuret
Journal:  J Neurochem       Date:  2008-09-18       Impact factor: 5.372

6.  The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity.

Authors:  Nichole E LaPointe; Gerardo Morfini; Gustavo Pigino; Irina N Gaisina; Alan P Kozikowski; Lester I Binder; Scott T Brady
Journal:  J Neurosci Res       Date:  2009-02       Impact factor: 4.164

Review 7.  Versatile somatic gene transfer for modeling neurodegenerative diseases.

Authors:  Ronald L Klein; David B Wang; Michael A King
Journal:  Neurotox Res       Date:  2009-08-11       Impact factor: 3.911

8.  Tau expression levels from various adeno-associated virus vector serotypes produce graded neurodegenerative disease states.

Authors:  Ronald L Klein; Robert D Dayton; Jason B Tatom; Cynthia G Diaczynsky; Michael F Salvatore
Journal:  Eur J Neurosci       Date:  2008-04       Impact factor: 3.386

9.  The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family.

Authors:  Salvatore Spina; Martin R Farlow; Frederick W Unverzagt; David A Kareken; Jill R Murrell; Graham Fraser; Francine Epperson; R Anthony Crowther; Maria G Spillantini; Michel Goedert; Bernardino Ghetti
Journal:  Brain       Date:  2007-12-07       Impact factor: 13.501

Review 10.  Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies.

Authors:  Jianhua Zhou; Qingming Yu; Tie Zou
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.